Biomarker ID | 771 |
PMID | 21980368 |
Year | 2011 |
Biomarker | miR-7-1*; miR-126*; miR-335; miR-28-5p; miR-339-3p; miR-339-5p; miR-542-5p |
Biomarker Basis | Expression Based |
Biomolecule | miRNA |
Source | Tissue |
Subjects | Humans |
Regulation | Downregulated: [miR-7-1* (8.88 fold); miR-126* (3.46b fold); miR-335 (2,42 fold); miR-28-5p (6.84 fold); miR-339-3p (-1.57 fold); miR-339-5p (5.26 fold); miR-542-5p (13.31 fold)] |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways Include (miR-126):- DNA-binding transcription factor activity, RNA polymerase II-specific; Gene expression (Transcription); RNA Polymerase II Transcription; Generic Transcription Pathway; nuclear chromatin Pathways Include(miR-28-5p):- synapse; nervous system development ; Golgi apparatus; cell junction; neuron projection Pathways Include(miR-339-3p):- generation of neurons; neurogenesis; nervous system development; synapse; neuron differentiation |
Experiment | Metastatic Vs Non Metastatic |
Type of Biomarker | Prognostic |
Cohort | From 1 patient, metastatic versus a non-metastatic prostate cancer xenograft line were dervied. |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p<0.001 |
Method Used | quantitative PCR (qPCR) |
Clinical | No |
Remarks | * indicates the less dominant arm in the miRNA |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | miR-7-1*, miR-126*, miR-335, miR-28-5p, miR-339-3p, miR-339-5p, miR-542-5p |